Literature DB >> 9815875

Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo.

L Cheng1, G Mantile, R Pauly, C Nater, A Felici, R Monticone, C Bilato, Y A Gluzband, M T Crow, W Stetler-Stevenson, M C Capogrossi.   

Abstract

BACKGROUND: Endovascular injury induced by balloon withdrawal leads to the increased activation of matrix metalloproteinases (MMPs) in the vascular wall, allowing smooth muscle cells (SMCs) to digest the surrounding extracellular matrix (ECM) and migrate from the media into the intima. The objective of this study was to examine the effects of a replication-deficient adenovirus carrying the cDNA for human tissue inhibitor of metalloproteinase-2 (AdCMV.hTIMP-2) on SMC function in vitro and neointimal development in the injured rat carotid artery. METHODS AND
RESULTS: Infection of cultured rat aortic SMCs at a multiplicity of infection of 100 with AdCMV.hTIMP-2 resulted in high-level expression of hTIMP-2 mRNA and protein secretion into the medium. Conditioned media (CM) from AdCMV. hTIMP-2-infected but not control virus (AdCMV.null or AdCMV. betagal)-infected SMCs inhibited MMP-2 activity on gelatin zymograms as well as the chemoattractant-directed migration of SMCs across reconstituted basement membrane proteins in the Boyden chamber assay. In contrast, AdCMV.hTIMP-2 CM had no effect on chemoattractant-directed migration of SMCs occurring in the absence of an ECM barrier or on the proliferation of cultured neointimal SMCs. Delivery of AdCMV.hTIMP-2 (2.5x10(9) pfu) to the carotid artery wall at the time of balloon withdrawal injury inhibited SMC migration into the intima by 36% (P<0.05) at 4 days and neointimal area by 53% (P<0.01) at 8 days and by 12% (P=NS) at 21 days after injury. AdCMV.hTIMP-2 had no effect on medial area.
CONCLUSIONS: Adenovirus-mediated hTIMP-2 gene transfer inhibits SMC invasiveness in vitro and in vivo and delays neointimal development after carotid injury.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9815875     DOI: 10.1161/01.cir.98.20.2195

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

Review 1.  The role of proteinases in angiogenesis, heart development, restenosis, atherosclerosis, myocardial ischemia, and stroke: insights from genetic studies.

Authors:  A Luttun; M Dewerchin; D Collen; P Carmeliet
Journal:  Curr Atheroscler Rep       Date:  2000-09       Impact factor: 5.113

Review 2.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 3.  Gene therapy for restenosis.

Authors:  R C Smith; K Walsh
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

4.  Viral vectors for vascular gene therapy.

Authors:  Lukas Fischer; Meir Preis; Anat Weisz; Belly Koren; Basil S Lewis; Moshe Y Flugelman
Journal:  Exp Clin Cardiol       Date:  2002

Review 5.  Gene transfer to the vasculature: historical perspective and implication for future research objectives.

Authors:  Sarah J George; Andrew H Baker
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

6.  Biomimetic-engineered poly (ethylene glycol) hydrogel for smooth muscle cell migration.

Authors:  Lin Lin; Junmin Zhu; Kandice Kottke-Marchant; Roger E Marchant
Journal:  Tissue Eng Part A       Date:  2014-01-09       Impact factor: 3.845

7.  The expression of tissue inhibitor of metalloproteinase 2 (TIMP-2) is required for normal development of zebrafish embryos.

Authors:  Jinsong Zhang; Shan Bai; Carmen Tanase; Hideaki Nagase; Michael P Sarras
Journal:  Dev Genes Evol       Date:  2003-05-08       Impact factor: 0.900

Review 8.  Gene therapy for restenosis: current status.

Authors:  Juha Rutanen; Johanna Markkanen; Seppo Ylä-Herttuala
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  A nonantibiotic chemically modified tetracycline (CMT-3) inhibits intimal thickening.

Authors:  Muzharul M Islam; Christopher D Franco; David W Courtman; Michelle P Bendeck
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

10.  Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model.

Authors:  Thomas C F Bodewes; Joel M Johnson; Michael Auster; Cindy Huynh; Sriya Muralidharan; Mauricio Contreras; Frank W LoGerfo; Leena Pradhan-Nabzdyk
Journal:  FASEB J       Date:  2016-09-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.